The role of microbiome alterations in cancer progression and its therapeutic potential in lung and blood cancers
Journal of Human Biology and Clinical Medicine · 2026
DOI: 10.63621/jhbcm/3.2026.31 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Human Biology and Clinical Medicine, 2026. Verfasst von Akmaral Argynbaeva und 4 weiteren Autor:innen.
Abstract (Originalsprache)
The aim of this study was to assess the role of microbiome dysbiosis in the pathogenesis of lung cancer and haematological malignancies. This observational clinical and laboratory study was conducted as a prospective, single-centre cohort study at the Professor Jerzy Gołcz Institute of Practical and Experimental Medicine at the Medical University of Warsaw. Patients with lung cancer and haematological malignancies were monitored clinically, and the composition and functional status of their microbiomes were assessed in the laboratory. Microbiome analysis was performed using 16S rRNA sequencing to evaluate bacterial diversity and taxonomic composition. Immunological parameters and levels of pro-inflammatory and anti-inflammatory cytokines were determined using an enzyme-linked immunosorbent assay. The study demonstrated that clinical treatment efficacy significantly depended on microbiome status. The objective response rate was 61.7% in patients with a preserved microbiome, 46.9% in those with moderate disturbances, and 33.8% in those with pronounced dysbiosis. Conversely, immunotherapy efficacy decreased from 64.8% to 31.5%, while the incidence of severe adverse effects increased to 38.4% and that of infectious complications to 51.2%. One-year overall survival decreased from 68.9% to 49.7% in lung cancer patients and from 74.3% to 53.8% in patients with haematological malignancies, accompanied by an increase in the risk of early disease progression to 31.0%. The data also showed that microbiome-modulating interventions, including probiotics, prebiotics, synbiotics and faecal microbiota transplantation, were associated with several positive effects. These included restoration of bacterial diversity, a reduction in metastasis rates to 18.5-22.3%, an improvement in treatment response by 16.2-21.0%, a decrease in systemic inflammation by 25-35%, and an increase in the tolerability of anti-cancer therapy by 18.5-23.0%. The practical value of this study lies in substantiating the feasibility of assessing microbiome status as a prognostic and potentially modifiable factor in lung cancer and haematological malignancies
Zitieren
APA
Argynbaeva, A., Kozhaliev, A., Kochorova, M., Omuralieva, G., & Abdykaarova, A. (2026). The role of microbiome alterations in cancer progression and its therapeutic potential in lung and blood cancers. Journal of Human Biology and Clinical Medicine. https://doi.org/10.63621/jhbcm/3.2026.31
Vancouver
Argynbaeva A, Kozhaliev A, Kochorova M, Omuralieva G, Abdykaarova A. The role of microbiome alterations in cancer progression and its therapeutic potential in lung and blood cancers. Journal of Human Biology and Clinical Medicine. 2026. doi:10.63621/jhbcm/3.2026.31
BibTeX
@article{Argynbaeva2026,
author = {Argynbaeva, Akmaral and Kozhaliev, Alaichy and Kochorova, Mayramkan and Omuralieva, Gulsana and Abdykaarova, Aigerim},
title = {The role of microbiome alterations in cancer progression and its therapeutic potential in lung and blood cancers},
journal = {Journal of Human Biology and Clinical Medicine},
year = {2026},
doi = {10.63621/jhbcm/3.2026.31}
}
EUVIMED